Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Clinical Trial of Olutasidenib in Japanese and Caucasian Healthy Adult Males
jRCT2031250348Phase 1Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of olutasidenib in acute myeloid leukemia (AML), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoints: Plasma concentrations of olutasidenib and Pharmacokinetic profile of olutasidenib. Started Oct 2025; status: completed.
02
Drugs
olutasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2031250348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250348.